

### MEDICATION PRIOR AUTHORIZATION REQUEST FORM

FAX this completed form to 1-833-546-1507

OR Mail request to: Pharmacy Services Prior Authorization Dept. 5 River Park Place East, Suite 210 | Fresno, CA 93720

Call 1-866-399-0928 to request a 72-hour supply of medication.

Pharmacy Services will respond via fax or phone within 24 hours of receipt of all necessary information, expect during weekends and holidays. For immediate response on weekends and holidays, NurseWise will answer your call.

VFEND<sup>®</sup> (Voriconazole)

(Maximum of 90 Days Approval) Note: Form must be completed in full. An incomplete form may be returned

				(ivia	Aiiiiai	01 0	,,,	.,0 / (	рр. о	vai, i	1010.	. 0	· iiias	. 50 (	Joinp	icica	rai			mpic	10 101		uy be	Total	iica				
Recipient's Medicaid ID# Date of Birth (MM/DD/YYYY)																													
Rec	ipien	t's F	ull N	ame	ı			1				1		ı		1	1	ı	1		1	ı	1	1		ı		ı	1
Pre	scrib	er's	Full N	Name	е																								
Pre	scrib	er's	NPI	1				1		_				1				ı										1	1
Pre	escriber Phone Number								Prescriber Fax								Number												
			-				-														-				-				
	Vfen	d® (v	oricor	nazo	le)				•	•	•					50 r	mg ta	b	•	•		] 4	0 ma	/ml s	usp.		•	•	•
	Vfend® (voriconazole) Initiation of therapy Continuation of therapy										200 mg tab							200 mg vials (IV)											
	00	JI I (II I (	atioi	1011	ισιαμ	Ју																		1	bs				kgs
Directions  Quantity/30  1. Please check all that apply: (Vfend not FDA approved for prophylactic approved)									Days Weight																				
1.	Plea	ise c	hec	k all	tha	t app	oly:	(Vfe	end	not	FDA	app	orov	ed fo	or pi	roph	ylac	tic t	hera	ру).									
		Cano Cano Diss	dider didia: emin	mia i sis c atec	n no of the	losis on-ne e esc ndidia s due	utro pha asis	peni gus of th	c pa ie sk	atient kin a	ts nd ir	nfect	ions	in th	e ab	odom	ien, k	kidne	ey, b										
2.	Has	pati	ent	rece	ivec	l trai	nspl	lant?	?	□ Y	es/				No														
	Type:								Date:																				
3.	Wha	at an	tifur	ngal	age	nt(s)	) ha	s the	pa	tient	t rec	eive	d in	the	pas	t 90	days	?											
	Drug Name:																Dates of Use:												
		R	easo	n fo																									
	Reason for Discontinuing:  Drug Name:										Dates of Use:																		
		R	easo	n fo	r Dis	cont	inuir	ng:																					
4.	Site																												
5.						erfor																							
				•		ıs El				•					-	lture				Biop			,						
6.	 Vfer				•												gist,	or		·	-	s Di	seas	e Sp	ecia	list			
	scrib	•			•							•																	
	UIRE																										es of	relat	ted
	. The														. a. uu		J. 14 1	33011	5116		,					John	JU 01	· Jiul	

Confidentiality Notice: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender (via return fax) immediately and arrange for the return or destruction of these documents. Distribution, reproduction or any other use of this transmission by any party other than the intended recipient is strictly prohibited.



## MEDICATION PRIOR AUTHORIZATION REQUEST FORM FAX this completed form to 1-833-546-1507

## OR Mail request to: Pharmacy Services Prior Authorization Dept. 5 River Park Place East, Suite 210 | Fresno, CA 93720

Call 1-866-399-0928 to request a 72-hour supply of medication.

Pharmacy Services will respond via fax or phone within 24 hours of receipt of all necessary information, expect during weekends and holidays. For immediate response on weekends and holidays, NurseWise will answer your call.

# VFEND<sup>®</sup> (Voriconazole)

(Maximum of 90 Days Approval) Note: Form must be completed in full. An incomplete form may be returned

### **Approved Indications:**

### **Invasive Aspergillosis:**

- a. The "Invasive Aspergillosis" diagnosis must be checked.
- b. **Initial treatment** will be approved for **1 month** in patients suspected of having a life-threatening invasive Aspergillus infection that meet the following criteria:
  - Have a diagnosis indicating they are immunocompromised or are currently receiving immunosuppressive drugs; AND
  - Patient has clinical manifestations (symptoms, signs, and radiological features) compatible with the diagnosis of invasive aspergillosis. (**Supporting documentation must accompany request.**)
- c. The **remaining 60 days of therapy** may be granted upon receipt of a positive **Platelia Aspergillus EIA test** (detects circulating galactomannam antigen), biopsy or culture. A copy of the original lab results is required.
- d. New test results must accompany request for continuation of therapy after initial 90 days of therapy.

#### **Treatment Failures:**

Patient must have documented treatment failure with one or more of the following (except in the case of invasive aspergillosis):

- Amphotericin B (Abelcet<sup>®</sup>, Fungizone<sup>®</sup>)
- Flucanozole (Diflucan®)
- Ketoconazole (Nizoral®)

Indication	PDL Alternatives (Current December 2007)							
Invasive Aspergillosis	Abelcet, amphotericin B, Fungizone							
Candidemia in non-neutropenic patients	Abelcet, amphotericin B, fluconazole, Fungizone							
Candidiasis of the Esophagus	Abelcet, amphotericin B, fluconazole, Fungizone, ketoconazole							
Disseminated candidiasis of the skin, and infections in the bladder wall, abdomen, kidney, and wounds	Abelcet, amphotericin B, fluconazole, Fungizone							
Scedosporium apiospermum and Fusarium species including Fusarium solani	Abelcet, amphotericin B, Fungizone							